California voters face Proposition 38, an $8.4 billion general obligation bond measure for immunology and immunotherapy research on the November 2026 ballot. Trader sentiment favoring rejection reflects primary concerns over annual General Fund repayment costs estimated at $500–600 million for roughly 20–25 years, alongside criticism that the initiative’s eligibility criteria and allocation structure heavily favor one UCLA-affiliated institute backed by its main proponent. Recent reporting has highlighted these design elements and the measure’s price mandates for any resulting therapies, while noting the context of federal research funding shifts. No major new polling or endorsements have shifted the outlook in recent weeks.